FORMYCON AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.2 EUR | +2.03% |
|
-0.92% | -2.70% |
| 01/07 | US FDA Approves Formycon's Biosimilar to Treat Serious Retinal Diseases | MT |
| 18/06 | Borse Frankfurt-News: Many winners and many losers (second-line stocks) | DP |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 1.02B | - | |||||
| 44.44B | - | |||||
| 37.99B | ||||||
| 37.75B | ||||||
| 30.78B | - | |||||
| 27.38B |
- Stock Market
- Equities
- FYB Stock
- FYB Stock
- Charts Formycon AG
- Sector Chart
